Journal: PLoS ONE

Article Title: Recombinant Neuregulin 1 Does Not Activate Cardiomyocyte DNA Synthesis in Normal or Infarcted Adult Mice

doi: 10.1371/journal.pone.0115871

Figure Lengend Snippet: (A) Use of BrdU to monitor cardiomyocyte DNA synthesis in non-injured adult mice receiving 9 consecutive daily injections of NRG1β1 (BrdU was delivered using a mini-osmotic pump). Left panel shows anti-β-galactosidase immune reactivity, middle panel shows anti-BrdU immune reactivity, and right panel shows the merged image. Arrow indicates a BrdU positive cardiomyocyte nucleus, arrowhead indicates a BrdU positive non-cardiomyocyte nucleus. Bar = 10 microns. (B) BrdU incorporation in the nuclei of the small intestine microvilli epithelial cells of an NRG1β1-treated mouse. Note the absence of BrdU signal in the muscularis mucosae zone (asterisk). Bar = 10 microns. (C) Use of 3 H-Thy to monitor cardiomyocyte DNA synthesis in non-injured adult mice receiving 9 consecutive daily injections of NRG1β1 ( 3 H-Thy was delivered as a single bolus 1 hour after the last NRG1β1 treatment). Arrow indicates a 3 H-Thy positive cardiomyocyte nucleus, arrowhead indicates a 3 H-Thy positive non-cardiomyocyte nucleus. Bar = 10 microns.

Article Snippet: Experimental mice were treated with recombinant human NRG1β1 (corresponding to the EGF domain, amino acid residues 176–256, #396-HB, R&D Systems, Minneapolis, MN), at a dose of 2.5 micrograms per mouse per IP injection, dissolved in saline containing 0.1% Bovine Serum Albumin (BSA); control mice received vehicle alone.

Techniques: DNA Synthesis, BrdU Incorporation Assay

Journal: PLoS ONE

Article Title: Recombinant Neuregulin 1 Does Not Activate Cardiomyocyte DNA Synthesis in Normal or Infarcted Adult Mice

doi: 10.1371/journal.pone.0115871

Figure Lengend Snippet: Cardiomyocyte DNA synthesis in adult MHC-nLAC mice following vehicle or NRG1β1 injection.

Article Snippet: Experimental mice were treated with recombinant human NRG1β1 (corresponding to the EGF domain, amino acid residues 176–256, #396-HB, R&D Systems, Minneapolis, MN), at a dose of 2.5 micrograms per mouse per IP injection, dissolved in saline containing 0.1% Bovine Serum Albumin (BSA); control mice received vehicle alone.

Techniques: DNA Synthesis, Injection, Control

Journal: PLoS ONE

Article Title: Recombinant Neuregulin 1 Does Not Activate Cardiomyocyte DNA Synthesis in Normal or Infarcted Adult Mice

doi: 10.1371/journal.pone.0115871

Figure Lengend Snippet: (A) Western blot demonstrating the levels of total Erk1/2 p42/p44, P-Erk1/2[Thr 202 /Thy 204 ] and RLC in mice treated with NRG1β1 or vehicle (hearts harvested and processed 90 minutes after treatment). Densometric quantitation revealed that NRG1β1 treatment resulted in a 987% increase in the level of ERK1 phosphorylation, a 5727% increase in the level of ERK2 phosphorylation, and a 21% increase in the level of phosphorylated RLC vs. vehicle-treated mice (p<0.01, Student’s t-test). (B) Non-cardiomyocyte 3 H-Thy nuclear labeling index in non-injured adult mice following 9 consecutive daily injections of NRG1β1 (5 sections analyzed from each of 4 independent mice) or vehicle (4 sections analyzed from each of 4 independent mice). *: p<0.05 vs. vehicle treated animals, Student’s t-test.

Article Snippet: Experimental mice were treated with recombinant human NRG1β1 (corresponding to the EGF domain, amino acid residues 176–256, #396-HB, R&D Systems, Minneapolis, MN), at a dose of 2.5 micrograms per mouse per IP injection, dissolved in saline containing 0.1% Bovine Serum Albumin (BSA); control mice received vehicle alone.

Techniques: Western Blot, Quantitation Assay, Phospho-proteomics, Labeling